The investigators determined that the protein interferon blocks the development of a population of immune cells known to cause asthma. These cells are members of a class of T lymphocytes, called T helper 2 cells, or Th2 cells.
Under normal circumstances, Th2 cells help protect against infections by secreting chemicals that induce inflammation; however, in some individuals, these Th2 cells can also promote allergic responses to normally harmless substances, including animal dander, pollens and pollutants. Once Th2 cells become reactive to these substances, they promote all of the inflammatory processes common to allergic diseases like asthma and atopic dermatitis.
The findings, available online and in the July 15 issue of the Journal of Immunology, suggest that interferon might be a valuable and readily available therapy for individuals with asthma.
"This finding is incredibly important, because humans are being treated with interferon for a variety of diseases, yet no one has tried treating asthma patients with interferon," said Dr. J. David Farrar, assistant professor of immunology and molecular biology at UT Southwestern and senior author of the study. "The current therapies for asthma are inhalers and steroids, both of which offer only temporary relief."
Asthma results in approximately 200,000 pediatric hospitalizations each year, more than for any other childhood disease. About 20 million people have been diagnosed with asthma in the U.S.
In the current study, the researchers showed in isolated human cells that interferon blocks the development of nascent Th2 cells and inhibits cells that already have become Th2 cells by interfering with a regulatory protein called GATA3, a transcription factor Th2 cells express to regulate their function.
"Interferon is blocking the development of these cells and their stability, and it's doing this by targeting the very transcription factor that regulates their development and stability in the first place," Dr. Farrar said. "By targeting this transcription factor, we've turned off the key component that regulates the entire process."
The findings, he said, provide proof-of-principle that targeting this particular group of cells with interferon might be an effective therapy for those with asthma.
"The study has confirmed that it's the Th2 cells that you really want to target," he said. "If you can stop a Th2 cell from ever developing, and if you can take a Th2 cell that has already become one and stop it from secreting these asthma-causing chemicals, then that's really the 'Holy Grail' of treating asthma."
The next step, Dr. Farrar said, is to study whether interferon will prevent Th2 cells taken straight from asthma patients from secreting the chemicals known to induce asthma.
"If interferon works against these cells, I think that would be an excellent basis for beginning a clinical trial and treating asthma patients," Dr. Farrar said. "We've been treating humans with interferon for a long time, so we don't have to go through early-phase safety trials. We already have information about its toxicity."
Other UT Southwestern researchers involved in the study were Jonathan Huber, lead author and student research assistant in immunology; Hilario Ramos, former student research assistant in immunology; and Dr. Michelle Gill, assistant professor of pediatrics and internal medicine.
The study was funded by the National Institutes of Health and Exxon Mobil Corp.
Visit http://www.utsouthwestern.org/allergy to learn more about UT Southwestern's clinical services for asthma and allergies.
This news release is available on our World Wide Web home page at www.utsouthwestern.edu/home/news/index.html
To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews
Kristen Holland Shear | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine